A new approach to reduce toxicity and improve quality of life in colon cancer patients receiving adjuvant chemotherapy

e15649 Background: We investigated the possibility of using accompanying therapy with enterosorbent in CRC patients receiving adjuvant chemotherapy. Methods: 40 pts (62 years [54.0-68.5]) with CRC (II-III) after radical surgery were randomized in 2 groups (1:1). Patients in the group 1 received ACT (XELOX), patients in group 2 received XELOX and enterosorbent "Polysorb" 30 mg orally, daily from 16 to 20 days of the ACT cycle. Results: The use of an enterosorbent can significantly reduce the manifestations of gastrointestinal toxicity: vomiting (5.0% vs 35.0%; p = 0.018), diarrhoea (5.0% vs. 40.0%; p = 0.008), flatulence ( 25.0% vs 70.0%; p = 0.004), constipation (0 vs 20.0%; p = 0.035) and abdominal pain (15.0% vs 50.0%; p = 0.018). In group 2, already by the 2nd cycle, the median scores on the QLQ-C30 symptomatology scale amounted to 22.0 points [14.0-28.5] vs 29.9 points [23.0-33.0] in the control group (p = 0.0441). By the 3 cycle in group 2, the average score on the QLQ-C29 symptomatic scale was 13.0±5.2 points (95% CI 10.5-15.4) and was significantly lower than in the control group (18.0±7.8 points (95% CI 14.3-21.6); p = 0.0224). When assessing the general condition according to the results of the analysis of the QLQ-C30 questionnaire, in the control group of patients there was a significant decrease in the number of points already by the beginning of the 2nd cycle of ACT - before the start of cycle 2 of ACT(p = 0.0369) and cycle 4 of ACT (p = 0.0447). Score of EQ-5D in the control group, significant decreases before 2 (from 84.9±6.4 points (95% CI 81.9-87.9) to 80.5 [77.55-86, 5]) (p = 0.0477) and 3 cycle ACT (from 80.5 [77.55-86.5] to 77.0±4.7 (95% CI 74.7-79.2)) (p = 0.0170), as well as a decrease in patient satisfaction with their condition at the time of the start of the 4th cycle of ACT compared with the baseline visit from 84.9±6.4 points (95% CI 81.9-87.9) to 75.7 ±6.7 points (95% CI 72.3-79.0) (p = 0.0001). Conclusions: The use of an enterosorbent as an accompanying therapy in CRC patients receiving ACT can significantly reduce the manifestation of chemotherapy toxicity and improve the quality of life of patients.